# Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

> **NCT05559645** · NA · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** DZD9008
- **DRUG:** DZD9008

## Key facts

- **NCT ID:** NCT05559645
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-18
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559645, "Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05559645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*